MPOX

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Siga
SigaNEW YORK, NY
1 program
1
Tecovirimat Oral CapsulePhase 31 trial
Active Trials
NCT05534984Terminated719Est. Feb 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
SigaTecovirimat Oral Capsule

Clinical Trials (1)

Total enrollment: 719 patients across 1 trials

NCT05534984SigaTecovirimat Oral Capsule

Study of Tecovirimat for Human Mpox Virus

Start: Sep 2022Est. completion: Feb 2025719 patients
Phase 3Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space